
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **June 2014**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation for Investors – June 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: June 17, 2014

By: /s/ Sigal Fattal

Sigal Fattal
Chief Financial Officer

EXHIBIT INDEX

<u>EXHIBIT NO.</u>	<u>DESCRIPTION</u>
99.1	A Slide Presentation for Investors – June 2014.



Introducing Evogene

18 June, 2014

Ofer Haviv
President & CEO



Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.






Table of contents

1.	Who we are
2.	Areas of activity
3.	Corporate and financial overview

Summary




Evogene at a glance

Our mission	<ul style="list-style-type: none"> ■ To improve plant productivity and performance by harnessing the power of plant genomics
Products and end-markets	<ul style="list-style-type: none"> ■ Core business - seed traits: biotech seeds (c.\$20bn) and conventional seeds (c.\$19bn) ■ Emerging businesses: ag-chemicals (c.\$54bn) and second generation feedstock for biofuels (castor bean)
What we do	<ul style="list-style-type: none"> ■ Currently mainly focused on identifying, validating and licensing genes to improve seed traits ■ Focus on traits with the highest economic value for farmers
Potential revenue sources	<ul style="list-style-type: none"> ■ Short to medium term: R&D and milestone payments from partners; castor seed sales ■ Long-term: royalties from seed traits and ag-chemicals
Core competencies	<ul style="list-style-type: none"> ■ Fundamental understanding of plant genomics and established track record ■ Unique proprietary computational platforms and scientific expertise for genomic discoveries ■ Addressing the industry's bottleneck of integrating and analyzing genomic 'big data'
Partnership model	<ul style="list-style-type: none"> ■ Collaborations with five of the world's leading seed companies ■ Monsanto is a strategic shareholder holding c. 9.8% <div>      </div>

The challenge and opportunity


The challenge: producing more with less

World population



World population (in billions) | Source: United States Census Bureau.

Arable land per capita



Hectares per capita, globally | Source: FAO.


The solution: increasing plant productivity and performance

Seed traits

Ag-chemicals

The opportunity: utilizing plant genomics to improve plant productivity

Strategic position in plant genomics



Our business

Our core business

Seed traits

- Yield and abiotic stress
- Biotic stress

- We focus on traits with the highest economic value for farmers
- We identify genes linked to key traits and license them to seed companies
- Our partners develop and plan to commercialize seeds containing our genes
 - ✓ Our patent portfolio covers c.4000 genes
 - ✓ We manage 23 product programs, comprised of various trait/crop combinations
 - ✓ 100's of our genes are undergoing field trial validation in our partners' pipelines
 - ✓ We continuously identify new genes under most of our product programs

Our emerging businesses


Ag-chemicals

- Emerging focus on identifying new targets for novel herbicides
- We also intend to develop chemical molecules as crop enhancers


Seeds

- Developing improved castor seeds as a viable alternative feedstock for biodiesel
- Completed three years of successful field trials in Brazil
- Recently signed agreement for commercial production in 2016

Our revenue model



Seed traits - product advancement



Note: Average duration may overlap and could be longer or shorter than estimated, depending on a range of factors, including, but not limited to, the type of crop and trait involved. Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

(1) Based on Company experience; (2) Based on Company estimations; (3) Based on Monsanto's Supplemental Toolkit, 2011.

Source: Average probability of success based on Monsanto's Supplemental Toolkit, 2011. The probabilities and related figures contained herein are provided strictly for illustrative purposes, and, except where expressly noted, do not reflect the estimates, calculations, or probabilities of any other source other than Monsanto's Supplemental Toolkit, 2011.

Partnerships with world leading seed companies

2013 2011 2008 2007	
2013 2011 2007	
2013 2009	
2010 2009 2007	
2010	 (2)

Combined
market share




- >10 collaboration agreements
- Portfolio of 23 product programs across various crops and traits
- 100s of genes being developed in partners' pipelines
- Most advanced genes in Phase 2
- Monsanto as a strategic shareholder holding c.9.8%

(1) Source: Phillips McDougall.

(2) Limagrain is the controlling shareholder of Vilmorin & Cie, a global leading seed manufacturer. Limagrain is also the sole owner of Biogemma, with which Evogene has an existing collaboration.

Our unique position

Solving the industry bottleneck - integration and analysis of genomic 'Big Data'



The key challenge in the industry has shifted from data generation to data integration and analysis

Our technology platform

Combining computational power and plant science






Table of contents

1.	Who we are
2.	Areas of activity
3.	Corporate and financial overview
Summary	


A photograph of a lush green cornfield under a bright blue sky with scattered white clouds. The corn plants are tall and healthy, with their characteristic long leaves and developing ears visible.

Strategic position in plant genomics



A. Seed traits - yield and abiotic stress

Collaborations to date



(1) Biogemma is a wholly owned subsidiary of Limagrain.

Yield & Abiotic stress - current product program pipeline



Potential near-term catalysts as more genes advance to Phase 2


Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are under development, collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

Collaboration with Monsanto

Focus on yield and abiotic stress - Aug. 2008, extended Nov. 2011 and Oct. 2013




- 8 Year collaboration
- Traits - yield, drought tolerance, fertilizer utilization
- Biotic stress traits - Fusarium resistance
- Crops - corn⁽¹⁾, soybean, cotton, canola
- c.\$68m in R&D and up-front payments by Monsanto over collaboration period
- Milestone payments + royalties based on sales
- Equity investment in Evogene - \$30m (including \$12m in recent IPO)



(1) Fusarium resistance activities are only in corn.


A. Seed traits - yield and abiotic stress

Current focus and future value drivers




B. Seed traits - biotic stress

Collaborations and programs to date



Biotic stress - current product program pipeline



Evogene Enters the Field of Insect Resistance

- Initially targeting corn rootworm and soybean aphids, two of the most devastating and challenging insects -

Rehovot, Israel – April 29, 2014 – Evogene Ltd. (NYSE: TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, disclosed today its entry into the field of plant insect resistance and control. The Company's initial activities in this important field are focusing on developing seed traits displaying resistance to two key insects, corn rootworm and soybean aphids.



Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

Collaboration with Syngenta

Focus on biotic stress - Jun. 2009, expanded and extended Sep. 2013



- Research period extended to March 2017
- Trait - Soybean Cyst Nematode (SCN) Resistance
- Main crop - soybean
- R&D reimbursement by Syngenta
- Milestone payments + royalties based on sales

The Syngenta logo, consisting of the word "syngenta" in a bold, blue, lowercase, sans-serif font, with a small green leaf icon above the letter 'y'. The logo is enclosed in a thin green rectangular border.

Gene discovery by Evogene

Development and commercialization by Syngenta

Soybean Cyst
Nematode




Model and target plant
validation and product
development

Regulatory



B. Seed traits - Biotic stress

Current focus and future value drivers




C. Ag-chemicals

Market and activity to date



Large market - c.\$54 billion in 2013


- ✓ **Herbicides**
 - Steady increase
- ✓ **Chemical crop enhancers**
 - Potential - address yield and abiotic stress traits




Source: Internalestimates, PhillipsMcDougall

Decreasing number of new active ingredients

- ✓ **Super weeds rising** - only ~20 Modes of Action (MOAs)
- ✓ **Innovation decreasing** - no new MOA in 20 years




Combining biology and chemistry to drive innovation



- Initiated in 2012, ag-chemicals is a new field for Evogene
- Discovery initiated - identifying targets within plant that can be inhibited by herbicides
- Dedicated computational platforms under development - leveraging tools from existing platforms and adding tailored new tools
- Initial discussions with potential partners⁽¹⁾

C. Ag-chemicals

Current focus and future value drivers



Leveraging plant genomics capabilities to plant-based industries

- Established in 2012 as a wholly owned subsidiary
- Primary product - castor bean seeds
- Core assets include proprietary castor bean varieties



Current market: industrial uses

Short term use

- Existing industries: biopolymers, lubricants, paints, etc.

The need

- High and volatile oil prices



Future market: Biodiesel

Long term use

- Second generation feedstock for biodiesel

The need

- Cost competitive and scalable feedstock production
- Not competing with land for food crops

Biodiesel production growing globally



Source: OECD and FAO Secretariats, Agricultural outlook 2011-2020, as of June 15, 2011.

D. Evofuel

Activity to date and future value drivers

Commercialization of advanced castor varieties expected in 2016

- Key markets: Brazil and Argentina
 - >5 million ha. potential for castor large scale production in Brazil
 - Downstream strategic partnerships in target markets
 -  leading agribusiness, 340,000 ha. in Brazil
 -  leading biodiesel producer in Argentina
 - Recently signed commercial production agreement with SLC for 2016

Potential value drivers

Brazil commercial sales

Strategic downstream collaborations

Development of next-generation varieties (no-ricin)



Brazil 2013



Argentina 2013



Israel 2013

Table of contents

1.	Who we are
2.	Areas of activity
3.	Corporate and financial overview



Corporate and financial overview

■ Corporate Identity


- Key milestones:
 - 2002 - spins off from Compugen (NASDAQ:CGN)
 - 2007 - lists on TASE (EVGN)
 - 2013 - lists on NYSE (EVGN)
- Market cap⁽¹⁾ c.\$420m, c.25m shares outstanding
- 200 FTEs, 87% R&D positions

■ Cash position

- c.\$124m in cash, cash equivalents, short and long term bank deposits and marketable securities (as of 31 March, 2014)
- Completed c.\$85m equity raising (gross proceeds) in November 2013


■ Financial position (as of 31 March, 2014)

- \$17.6m in revenues in FY13, \$3.9m in 1Q14, mostly R&D payments



- Total R&D costs⁽²⁾ were \$21.2m in FY13, and \$5.2m in 1Q14, comprising:

- COGS
- Independent R&D expenses



Summary

- 1 Strategic position in plant genomics - engine for agricultural innovation
- 2 Unique technology platform, combining expertise in plant science and cutting-edge computational tools
- 3 Diversified product portfolio with multiple paths of commercialization
- 4 Partner of choice for industry leaders
- 5 Multiple future value drivers



Thank You!



Agriculture Productivity - Market and Offering

18 June, 2014

Ido Dor, Director
Business Development



Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Table of contents

1.	Agriculture productivity
2.	Evogene's offering
3.	Summary




Ag Productivity Market Drivers

Supply and demand gap



Decreasing arable land per capita


(Hectares per capita, globally)



Source: FAO.

Importance of productivity


Indexed area and production trends ⁽¹⁾



Source: USDA.

Change in agricultural yields

10-year rolling average change in yield ⁽¹⁾




Source: USDA.

Maintaining and accelerating agricultural productivity is a central component of achieving global food and nutrition security

Ag Productivity - Grower's Point of View

Example - corn




Ag Productivity Inputs

Seeds and Ag Chemicals market (2013)




Seeds - ~\$40B market



'Seed internal' (traits & seeds)
Impacting ag productivity by
improving the seeds

Ag Chemicals - \$54B market



'Beyond the seed'
Impacting ag productivity by
applications applied externally

A combined market of ~\$94B

Source: Phillips McDougall, 2013

At the Forefront of Plant Genomics


Table of contents

1.	Agriculture productivity
2.	Evogene's offering
3.	Summary




Strategic Position In Plant Genomics

Evogene's offering



Commercial Seeds Market


Global market development 2003 - 2013



Biotechnology-based crops are growing at ~18% per year since the technology became commercial in the late 1990s

Industry Leaders

Commercial seed sales (US\$ millions, 2012)




Source: Phillips McDougall, 2012

Seven industry leaders responsible for ~64% of seed market


Generating Revenues From Biotech Seeds

Current and untapped market potential




Strategic Position In Plant Genomics

Evogene's offering



Seed traits - yield and abiotic stress

Current focus and future value drivers



Gene2Product Platform

Gene optimization



Evogene Announces Launch of Gene2Product Computational AgBio Platform

January 29th, 2013

Platform designed to improve plant trait efficacy and probability of success of novel seed products by optimizing 'mode of use' for genes of interest

Rehovot, Israel – January 29, 2013 – Evogene Ltd. (TASE: EVGN), a leading developer of improved plant traits for the food, feed and biofuel industries, announced today the launch of Gene2Product™ version 1.0, a unique integrated computational platform for improving trait efficacy by high throughput optimization of gene function in the target crop ('mode of use') as part of the development process for biotechnology seed products. Evogene has already entered into agreements to utilize Gene2Product™ to optimize the performance of certain genes it has discovered for use in the development pipelines of its partners.

Evogene Enhances Predictive Gene Stacking Capabilities

March 6th, 2014

Combining multiple genes increasingly seen as essential for addressing complex traits

Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in improving crop productivity for the food, feed and biofuel industries, announced today enhanced capabilities for gene stacking prediction with the introduction of PlaNet (Plant Networks) version 2.0 computational platform. The upgraded version includes more than doubling of the platform's interaction data sources and types, and improved algorithms for data analysis.

Monsanto and Evogene Extend and Expand Collaboration for Crop Improvement

October 28th, 2013


**Extension of existing collaboration covering yield, environmental stress and fertilizer utilization in corn, soybean, cotton and canola to August 2016;
Expansion of the collaboration to include a program for resistance to Stalk Rot disease caused by Fusarium species**

Monsanto Company and Evogene Ltd. (TASE: EVGN) announced today the extension and expansion of their research and development collaboration. The collaboration, initially signed in 2008 and later extended in 2011, has focused on identifying key plant genes related to yield, environmental stress and fertilizer




Strategic Position In Plant Genomics

Evogene's offering



Seed traits - Biotic stress

Current focus and future value drivers



Insect Resistance

A new field for Evogene



Evogene Enters the Field of Insect Resistance

April 29th, 2014

Initially targeting corn rootworm and soybean aphids, two of the most devastating and challenging insects

Evogene Ltd. (NYSE; TASE: EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, disclosed today its entry into the field of plant insect resistance and control. The Company's initial activities in this important field are focusing on developing seed traits displaying resistance to two key insects, corn rootworm and soybean aphids.

The world-wide damage to crop production due to insects, currently estimated at 20% of global yield, is expected to become an even greater problem in coming years. Among the trends underlying this concern are the growing resistance of insects to currently available insect control products, primarily biotechnology seeds and ag-chemicals, and ongoing regulatory pressures to reduce the widespread use of chemical-based products




Insect Resistance Market

Need for novel solutions



Growing Market



Emerging Resistance



BT Focused Solutions

Novel products in pipelines include several MOAs:

- Still mainly BT-focused
- Mostly targeting the same insects

INSECT	GENUITY		NEXT-GENERATION	
	GENUITY BOLLGARD II	GENUITY BOLLGARD II	GENUITY BOLLGARD II	GENUITY BOLLGARD II
TOBACCO BUGHOMER				3
COTTON BOLLWORM	2		3-4	
FALL ARMYWORM	1		3-4	
PINK BOLLWORM	2		3	
TOBACCO WORM	1		3-4	

Source: companies official publications

BT - One Solution Does Not Fit All

"Stink bug population spreading across USA"
USA Today, 3/25/11



Insect Resistance GM Solutions

Products of focus



Rootworm - Corn

- Top insect for major crop - trait value estimated at ~\$1,000M*
- Resistance rising to existing solutions
- Partner indication for need
- Other top insects from order

Addressed insect



Aphids - Soybean

- Top insect for major crop - trait value estimated at >\$500M*
- No biotechnology solutions
- Partner indication for need
- Relevant across crops - Soy → Corn → Cotton
- Other top insects from order


Unaddressed insects



*Evogene internal estimates



Strategic Position In Plant Genomics

Evogene's offering



The Ag Chemicals Market


Key market figures



The science of crop protection is expanding beyond traditional Ag Chemicals to include new technologies to develop more effective products

Industry Leaders

Ag chemicals sales (2013)




Source: Phillips McDougall

Six industry leaders are responsible for ~80% of the Ag Chemicals market

Ag-chemicals

Current focus and future value drivers



Legend

- Current focus
- Future opportunities


The Herbicide Industry

The need



Growing need for innovation


Modes of Action (MOA) available



Source: Phillips McDougall.

Weed resistance is soaring

of species with multiple resistance



Source: WSSA.


Regulation pressure



No new herbicide with a new 'Mode of Action' introduced in the past 20 years

Convergence of Plant Biology and Chemistry

First milestone achieved



Novel herbicides



PoinTar

Target discovery platform

Evogene Launches Target Discovery Platform for Novel Herbicides

February 11th, 2014


Computationally based PoinTar platform represents key milestone in program designed to address unmet need for new modes of action for herbicides

Validation of new MOA



Ag-chemicals

Current focus and future value drivers



Ag-Biologicals

The market



Estimated to reach ~ \$7.5B by 2020



Piper Jefferie's growth estimates

Ag-Biologicals M&As & collaborations



Sources - MBI presentation, Biopesticide conference Dec 2013


Short Time to Product, Significantly Lower Development Cost



Source: Internal Evogene estimates

Strategic Position In Plant Genomics

Evogene's offering



Evofuel - Seed Company

Castor bean - first crop of focus



Current market: industrial uses

- Existing industries: biopolymers, lubricants, paints, etc.
- Global production 2013: c.650,000 ton → rigid demand
- Main exporters: EU, U.S., China

The need

- Secure stable supply at stable price

Strategic market: Biodiesel

- Global biodiesel production (2013) - c.27bn litres
- Brazil, Argentina:


Brazil to Increase Biodiesel in Fossil Fuel
By Luis Antonio de Jesus, 2014

Measure announced last week in Brazil will reduce diesel imports and pollution.

The need

- Cost competitive and scalable feedstock production


Soybean & castor oil prices in past year



Sources: Bloomberg data;
Grain Report, Brazil Biofuel
Annual Report 2013

From Seed to Product

Value chain already exists



Sources: Internal Evogene estimates

Evofuel

Activity to date and future value drivers



Commercialization of advanced castor varieties expected in 2016

- Key markets: Brazil and Argentina
- >5 million ha. potential for castor large scale production in Brazil
- Downstream strategic partnerships in target markets
 -  leading agribusiness, 340,000 ha. in Brazil
 -  leading biodiesel producer in Argentina
- Recently signed commercial production agreement with SLC for 2016

Potential value drivers

Brazil commercial sales

Strategic downstream collaborations

Development of next-generation varieties (no-ricin)



Brazil 2013



Argentina 2013




Israel 2013

Company estimations

Unique Agricultural Opportunity

Rotation model with soybean



SLC background

- Large scale agribusiness
- managing 340,000 ha of land across Brazil
- 16 farms located in Brazilian Savanna
- Targeting 700,000 ha in 2020/21

SLC
Agrícola



Commercial production of castor under SLC collaboration expected in 2016

Recent Updates

Achievement of development and commercialization milestones



Evogene Subsidiary Completes Three Years of Successful Field Trials for Improved Castor Seeds

September 16th, 2013

Evofuel's castor seeds are expected to be commercially available in 2016

Evogene Ltd. (TASE: EVGN), a plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, today announced that its wholly owned subsidiary, Evofuel Ltd., has completed three years of successful field trials in Brazil for the development of castor bean as an alternative feedstock for production of biodiesel and other industrial uses.

The field trials, which were conducted in cooperation with SLC A of Brazil's largest landowners and leading agriculture businesses, strong yield performance of Evofuel's proprietary castor seed va rain-fed conditions in northeast Brazil, and supported the use of competitive biodiesel feedstock. Moreover, Evofuel's castor seed



Evogene Subsidiary and SLC Agricola Sign Collaboration Agreement for Commercial Production of Castor Bean in Brazil

The New York Times
Wednesday, March 26, 2014

Published: March 25, 2014

- Sales of castor bean grain under the collaboration are expected in 2016 -

REHOVOT, Israel & PORTO ALEGRE, Brazil--(BUSINESS WIRE)--Mar. 25, 2014-- Evogene Ltd. (NYSE, TASE:EVGN), a leading plant genomics company specializing in enhancing crop productivity for the food, feed and biofuel industries, and SLC Agricola S.A. (Bovespa: SLCE3; ADR's: SLCJY; Bloomberg: SLCE3:BZ; Reuters: SLCE3.SA), one of Brazil's largest landowners and agriculture businesses, announced today the signing of a collaboration agreement between SLC and Evofuel Ltd., Evogene's wholly-owned subsidiary, for the commercial production of Evofuel developed castor bean varieties in Brazil, expected to take place during 2016. Evofuel focuses on the development of high yielding castor bean seeds as a second-generation feedstock for the growing biofuel and other industrial markets.




Table of contents

1.	Agriculture productivity
2.	Evogene's offering
3.	Summary



Agriculture Productivity Inputs

Seeds and Ag Chemicals market development 2003-2013




Source: Phillips McDougall.

Utilizing plant genomics to improve plant productivity - potential addressable market of ~\$94B

Strategic Position In Plant Genomics

Main value drivers





Thank You!



Evogene Technology Platform

18 June, 2014

Dr. Alin Sela-Brown
Director, Labs and QA


At the Forefront of Plant Genomics

Agenda


1.	Introduction
2.	Technology Platform Units
3.	Integration & Synergy
4.	Summary



Strategic position in plant genomics



Strategic position in plant genomics




Agenda


1.	Introduction
2.	Technology Platform Units
3.	Integration & Synergy
4.	Summary




Technology Platform Internal Structure



Computational Genomics



Technology Platform Internal Structure



Labs & Tissue Culture



Molecular Lab

RACE & Cloning


Over 1,200 genes per year, 30 species



Tissue culture

Transformation & Validation assays

Arabidopsis , Brachypodium, Tomato, Canola
6,000 transformed plants each year



QA


SOP, QC, Lab notebooks, System calibrations
Safety , regulation











Supporting special requirements of Evogene research activity:


- Preparation of hundreds of DNA, RNA & special NGS libraries
- HTP genotyping of multiple species - Genotyping By Sequencing, padlocks etc
- Tailored projects - Next Generation Interactome, copy number determination

Technology Platform Internal Structure




	Seed propagation	Propagation of seed Core Collections <u>15</u> crops, 7 Core collection, support over 40 experiments and field trials	
	Seed bank	Management of seed inventory and regulation <u>79</u> species 4,273 imported lines Import / export - new lines are introduced each year	
	Model plants	Transgenic seed propagation & Validation assays 16 type of assays in Arabidopsis, 6 type assays in Brachypodium <u>500,000</u> plants per year	
	Target plants	Experiment growth activity and phenotypic collections <u>40</u> experiments per year 15 different crops , dozen treatments, in two main season	

Technology Platform Internal Structure



Information Technology & Data Management






Agenda

1.	Introduction
2.	Technology Platform Units
3.	Integration & Synergy
4.	Summary



Validation Technologies

Plant POC example





Agenda

1.	Introduction
2.	Technology Platform Units
3.	Integration & Synergy
4.	Summary



Expanding Infrastructure



Expanding Infrastructure



People



At the Forefront of Plant Genomics



Thank You!